Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Kaohsiung J Med Sci ; 25(10): 559-61, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19767262

RESUMO

Cavernous hemangioma is a congenital, benign vascular tumor that occurs in the deep dermis and subcutaneous tissue. Scrotal hemangiomas are rare entities and are usually diagnosed in childhood. Adult scrotal hemangiomas are also extremely rare. They are infrequently encountered in adults because they are usually removed in childhood. Urologists often face difficulties in deciding surgery to treat a genital cavernous hemangioma. Here, we report a case of scrotal cavernous hemangioma that involved the entire penis and scrotum, and extended to the perineum in a 44-year-old man, and we review the literature.


Assuntos
Neoplasias dos Genitais Masculinos/cirurgia , Hemangioma Cavernoso/cirurgia , Pênis/cirurgia , Períneo/cirurgia , Adulto , Neoplasias dos Genitais Masculinos/diagnóstico , Neoplasias dos Genitais Masculinos/patologia , Hemangioma Cavernoso/diagnóstico , Hemangioma Cavernoso/patologia , Humanos , Masculino , Pênis/patologia , Períneo/patologia
2.
Int J Dermatol ; 43(1): 63-6, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14693026

RESUMO

BACKGROUND: Due to the high rate of recurrence, seborrheic dermatitis (SD) represents a therapeutic problem. AIM: To evaluate the role of oral itraconazole in the treatment of SD. PATIENTS AND METHODS: Thirty-two patients with SD were enrolled in the study. All topical and oral treatments were stopped. The patients applied 1% hydrocortisone cream twice daily for 1 month. In addition, they took itraconazole, 200 mg/day, during the first week of the first month and then hydrocortisone cream was stopped and itraconazole (200 mg/day) was given on the first 2 days of the following 11 months. The patients were followed for 2 months without medicine. The severity score was measured at the initial evaluation, and at the first, 12th, and 14th months. RESULTS: Twenty-eight patients completed the study. There was a statistically significant decrease in the mean severity score at the first, 12th, and 14th months. On the final evaluation at the 12th month, 19 of the 28 patients showed a complete improvement, and three patients showed a slight improvement. CONCLUSIONS: This study indicates that itraconazole plays an important role in the treatment of SD.


Assuntos
Antifúngicos/uso terapêutico , Dermatite Seborreica/tratamento farmacológico , Itraconazol/uso terapêutico , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...